Phosphonate Factor D Inhibitors for Complement Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by the complement pathway, such as age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, lack effective small molecule inhibitors for Factor D, leading to inadequate management of excessive activation and associated inflammatory responses.
Innovation Solution
Development of phosphonate compounds that inhibit the complement pathway by targeting Factor D, specifically designed to modulate immune responses and reduce detrimental complement activity in disorders associated with the alternative, classical, and lectin pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for complement pathway disorders are used, then existing therapy options are available, but effective small molecule inhibitors for Factor D are lacking leading to inadequate management of excessive activation
Solution Approach 1:
The patent applies parameter changes by developing small molecule inhibitors with specific chemical structures (Formula I) that target Factor D. The compounds feature variable substituents (R1-R6, R9-R10) that can be modified to optimize binding affinity and selectivity, representing systematic parameter optimization to overcome the lack of effective small molecule inhibitors for complement pathway disorders
2Reliability
If the complement pathway is activated to clear pathogens, then immune defense is enhanced, but excessive activation leads to detrimental inflammatory responses and tissue damage
Solution Approach 1:
The patent implements feedback control by designing Factor D inhibitors that selectively modulate the alternative complement pathway. The compounds provide negative feedback to excessive complement activation by blocking Factor D enzymatic activity, thereby reducing harmful inflammatory responses while preserving necessary immune defense functions through pathway-specific inhibition
3Object-generated harmful factors
If Factor D is inhibited to reduce complement activation, then excessive complement activity is dampened, but the ability to clear pathogens may be compromised
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (indole or indazole core with particular substituent patterns) that confer selective binding to Factor D. This localized molecular design enables selective inhibition of the alternative pathway while preserving other complement pathways (classical and lectin) that are essential for effective pathogen clearance
Data Source
AI summary
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.